STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit

AI Summary

Kyverna Therapeutics reported encouraging data for its cell therapy targeting autoimmune diseases, bringing the company closer to launching the first approved treatment of its kind. Many patients remained off other therapies during the study, indicating sustained benefits.

Kyverna Therapeutics is one step closer to launching the first cell therapy for an autoimmune disease, with new data in hand showing many patients remained off of other therapies a…